| Document |
Document Title |
|
WO/2017/138838A1 |
The invention relates to salts and hydrates of arylcycloalkylamine derivatives of general formula (I) and formula (II), where in formula (I), R1 and R2 signify H, a linear or branched alkyl (C1, C4), a linear or branched alkoxy (C1, C4),...
|
|
WO/2017/133675A1 |
The present invention relates to a method for preparing a high-purity cyclohexenone long-chain alcohol represented by formula I. The compound represented by formula I is prepared by using metal-mediated Barbier reaction. The method of th...
|
|
WO/2017/131221A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions cont...
|
|
WO/2017/130148A1 |
The present disclosure relates to an in vitro method for enhancing engraftment of neurosensory precursor cell comprising the step of contacting an isolated neurosensory precursor cell prior to a transplantation in a subject in need there...
|
|
WO/2017/126275A1 |
The means according to the present invention are: a compound represented by formula (1); a liquid crystal composition containing this compound; and a liquid crystal display element comprising this composition. In formula (1), each of R1 ...
|
|
WO/2017/125775A1 |
The present invention relates to the use of a pyrenocine compound or a pyrenochaetic acid compound for the prevention or the treatment in algae of diseases induced by protistan pathogens. The present invention also relates to a new pyren...
|
|
WO/2017/122495A1 |
A ceramidase inhibitor which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt thereof; and a ceramide synthesis promoter which comprises a compound represented by formula (II) or a pharmaceutically ac...
|
|
WO/2017/118945A1 |
The present invention relates to a premix of dapagliflozin with lactose, processes for its preparation, and pharmaceutical composition thereof. The invention also relates to a process for the preparation of an amorphous dapagliflozin and...
|
|
WO/2017/114102A1 |
The present invention belongs to the field of macromolecules and biomedical materials, and relates to a polymer, a block copolymer comprising a segment of the polymer, methods for preparing the polymer and the block copolymer, a micelle ...
|
|
WO/2017/111380A1 |
The present invention relates to a novel salicylic acid derivative, a method for preparing the same, and a cosmetic composition for whitening comprising the same. The compound exhibits a skin whitening effect by acting on tyrosinase, whi...
|
|
WO/2017/106649A1 |
This disclosure is related to methods for producing anhydroryanodol, ryanodol, or analogues thereof and novel compounds prepared thereby.
|
|
WO/2017/095121A1 |
The present invention relates to a novel hydroxyl pyranone compound, a method for producing same, and a cosmetics composition comprising the compound. The hydroxyl pyranone compound according to the present invention exhibits markedly im...
|
|
WO/2017/095098A1 |
The present invention relates to a novel hydroxyl pyranone compound, a method for producing same, and a cosmetics composition comprising the compound. The hydroxyl pyranone compound according to the present invention exhibits markedly im...
|
|
WO/2017/093209A1 |
The present invention relates to a process for preparing 3-amino tetrahydropyrans and, more particularly, to an improved method for synthesizing a 2,3,5-substituted tetrahydropyran derivative, intermediate being used in the preparation o...
|
|
WO/2017/095319A1 |
The invention relates to compounds of Formula (I), wherein the variables are as defined in the claims, which are useful in the treatment and/or prevention of bacterial infections in a subject. The invention further relates to the use of ...
|
|
WO/2017/084644A1 |
The invention relates to a new crystalline form of Canagliflozin of formula I, with its systematic name (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)meth
yl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4
,5-triol5 a...
|
|
WO/2017/079867A1 |
There is provided a polymerizable composition, by which discoloration or alignment defects are less likely to occur when a filmy polymer, which is obtained by adding a polymerizable compound to the polymerizable composition and polymeriz...
|
|
WO/2017/083434A1 |
The present teachings relate to pyrone derivatives, pharmaceutical compositions thereof, and methods of using such compounds to treat bacterial infections.
|
|
WO/2017/078927A1 |
Novel compounds having a formula (I), embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a s...
|
|
WO/2017/076264A1 |
The present invention relates to a class of compounds as shown in general formula I or pharmaceutically acceptable salts thereof, a preparation method therefor, application thereof as a small molecule tool that functions as a GPR84 agoni...
|
|
WO/2017/071575A1 |
Provided is a liquid crystal compound of general formula I having a negative dielectric anisotropy. The liquid crystal compound has a large dielectric anisotropy absolute value, a high voltage holding ratio, a good intersolubility, and a...
|
|
WO/2017/070718A1 |
The invention provides compounds for use as medicaments, which act by inhibiting CYP17A1 and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer especially prostate cancer and breast cancer. The compound...
|
|
WO/2017/070084A1 |
The disclosed subject matter provides N- hydroxylsulfonamide derivative compounds of formulae (I), (II) or (III) as drawn below, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using ...
|
|
WO/2017/060420A1 |
The present invention provides novel cell-permeable fumarate acyl mercaptoethylamines (FAMs) which have cellular effects including induction of Nrf2 and inhibition of the NFkB pathway. These compounds have utility in medicine including t...
|
|
WO/2017/051319A1 |
Provided are compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R 1, R 2, R a, R b, n, x, y and z are as defined herein, which are active as modulators of retinoid-related orphan receptor g...
|
|
WO/2017/051354A1 |
Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the p...
|
|
WO/2017/049172A1 |
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of condi...
|
|
WO/2017/048817A1 |
The present invention includes crystalline forms of N-acetylneuraminic acid (NeuAc) and crystalline forms of salts and/or solvates of N-acetylneuraminic acid (NeuAc). Furthermore, the present invention provides compositions comprising th...
|
|
WO/2017/049091A1 |
Provided herein are compounds which intercalate into the DNA of a cell and are capable of crossing the blood brain barrier of a formula provided herein. Pharmaceutical compositions of the compounds and methods of treating cancer, for exa...
|
|
WO/2017/044572A1 |
A genus of arylsulfonamide derivatives of ring constrained diarylamino sulfonamide compounds is disclosed. The compounds are of the following genus:. The compounds induce FOXO1 transcription factor translocation to the nucleus by modulat...
|
|
WO/2017/014013A1 |
A compound represented by formula (1). For example, R1 represents an alkyl group having 1-15 carbon atoms; MES represents a mesogenic group having at least one ring; Sp1 represents a single bond or an alkylene group having 1-10 carbon at...
|
|
WO/2017/013265A1 |
The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs).The present invention further ...
|
|
WO/2017/010399A1 |
Provided are compounds having RORγt inhibitory effects represented by formula (I). Compounds represented by formula (I) (wherein L represents -NR1ACO-, -SO2- or the like, A represents a substituted or unsubstituted aromatic carbocyclic ...
|
|
WO/2017/007756A1 |
This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or ...
|
|
WO/2016/205202A1 |
The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertensi...
|
|
WO/2016/198374A1 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2016/179645A1 |
The present disclosure relates to 4H-pyran compounds of formula (I) and their use in therapy, to compositions and agents comprising said compounds, to methods of treatment using said compounds, and their use in the manufacture of medicam...
|
|
WO/2016/181567A1 |
The present invention provides a modified milk powder containing a biological active ingredient 1,5-anhydro-D-glucitol (1,5-AG). The present invention is a modified milk powder containing 1,5-AG at a concentration of 7.7 to 3850 μg/g.
|
|
WO/2016/182036A1 |
The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemot...
|
|
WO/2016/178148A1 |
The present invention relates to a process for the preparation of amorphous dapagliflozin. The present invention relates to 2,3-butanediol solvate of dapagliflozin and process for its preparation.
|
|
WO/2016/176560A1 |
The present invention provides unified synthesis of the CI -CI 9 building blocks of halichondrins and analogs theoreof using selective coupling of poly-halogenated nucleophiles in chromium-mediated coupling reactions. The present inventi...
|
|
WO/2016/172496A1 |
Provided are novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSDl. Also provided are pharmaceutical compositions ...
|
|
WO/2016/172114A1 |
New methods of preparing bridged bi-aromatic ligands are disclosed. The methods employ direct di-ortho-lithiation of aromatic rings of bridged protected bi-aromatic diphenols. The ligands may be used to prepare transition metal compounds...
|
|
WO/2016/171165A1 |
A medicine for preventing and/or treating diseases caused by the activation of caspase-1, for example, chronic inflammations or autoinflammatory diseases, said medicine comprising as an active ingredient a compound represented by formula...
|
|
WO/2016/168058A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2016/167361A1 |
The purpose of the present invention is to provide a novel method for producing an organic compound substantially free of Pd in an inexpensive and simple manner. The present invention pertains to a method for producing an organic compoun...
|
|
WO/2016/168056A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2016/162644A1 |
The present invention relates to the use of sodium dithionite to reduce at least one aldehyde or ketone function of a carbohydrate, C-glycoside, oligosaccharide, or water-soluble polysaccharide in the absence of a water-immiscible organi...
|
|
WO/2016/162405A1 |
The present invention relates to compounds and compositions for use in methods of treating and/or preventing conditions, disorders or diseases that are mediated or caused by a virus.
|
|
WO/2016/161286A1 |
There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, suc...
|
